Anebulo Pharmaceuticals IncNASDAQ:ANEB
- LAST PRICE1.4600
- TODAY'S CHANGE (%)-0.0400 (-2.6667%)
- Bid / Lots1.4500/ 1
- Ask / Lots1.5900/ 18
- Open / Previous Close1.4800 / 1.5000
- Day Range
- 52 Week Range
- Volume3,491
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ANEB |
|---|---|---|
| 10:11 ET | 600 | 1.48 |
| 10:22 ET | 100 | 1.4622 |
| 11:07 ET | 500 | 1.43 |
| 11:14 ET | 155 | 1.42 |
| 11:16 ET | 100 | 1.42 |
| 03:30 ET | 100 | 1.58 |
| 03:42 ET | 100 | 1.48 |
| 03:44 ET | 199 | 1.5233 |
| 04:00 ET | 211 | 1.46 |
Nov 19, 2024
DJ Anebulo Pharmaceuticals Price Target Maintained With a $8.00/Share by Benchmark, from 8:55AM ET on Tuesday Nov 19, 2024 by Dow Jones
8:55AM ET on Tuesday Nov 19, 2024 by Dow Jones
Nov 13, 2024
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates, from 4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
4:05PM ET on Wednesday Nov 13, 2024 by Dow JonesPress Release: Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates, from 4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Anebulo Pharmaceuticals Inc | 37.9M | -4.8x | --- |
RAPT Therapeutics Inc | 37.7M | -0.4x | --- |
Reviva Pharmaceuticals Holdings, Inc. | 38.1M | -1.0x | --- |
Calidi Biotherapeutics Inc | 37.5M | -0.4x | --- |
CEL-SCI Corp | 36.6M | -1.0x | --- |
OS Therapies Inc | 39.1M | -5.5x | --- |
Company Information
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company. It is engaged in developing treatments for cannabis toxicity, such as unintentional cannabis poisoning, acute cannabinoid intoxication (ACI) and the landscape of acute cannabis-induced conditions. Its lead product candidate is selonabant, a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1), the primary receptor involved in the psychotropic effects of cannabinoids, with the potential to address the unmet medical need for a therapy to treat cannabis toxicity. Selonabant is orally bioavailable, rapidly absorbed, and has also been formulated for intravenous treatment. Selonabant has completed dosing in a Phase II clinical trial evaluating its utility in blocking and reversing the negative effects of acute cannabinoid intoxication. It is also prioritizing the advancement of a selonabant IV formulation as a potential treatment for pediatric patients with unintentional cannabis poisoning.
Contact Information
- Headquarters
- Jfl Capital Management 1017 Rr 620 S, Suite 107LAKEWAY, TX, United States 78734
- Phone
- 512-598-0931
- Fax
- ---
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $37.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 25.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -1.07 |
EPS | $-0.31 |
Book Value | $0.15 |
P/E Ratio | -4.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
